Table 1 Demographic characteristics of individuals participating in this study.

From: Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes

Demographic

DM (n = 40)

non-DM (n = 30)

P

Age (years)

Median (range)

55 (38–69)

53 (37–70)

0.1539

Sex (%)

Female

68

77

ND

Body mass index (kg/m2)

Median (range)

25 (18–36)

25.1 (18–36.5)

0.8308

Fasting blood sugar (mg%)

Median (range)

128.5 (89–435)

90.5 (55–137)

<0.0001

HbA1c (%)

<6.5

22.5

ND

ND

6.5–8.4

37.5

>8.5

40

Type of anti-diabetic medication

n (%)

  

ND

   Metformin only

 

12 (30)

  

   Glibenclamide only

 

10 (25)

  

   Metformin + glibenclamide

 

18 (45)

  

Duration of anti-diabetic medication (months)

median (range)

   

   Metformin only

 

29 (9–48)

 

0.0008a,

   Glibenclamide only

 

91.5 (36–228)

 

nsb,

   Metformin + glibenclamide

 

33.5 (20–137)

 

0.0337c

History of influenza vaccination

(%)

   

   previously vaccinated

 

90

10

ND

   not previously vaccinated

 

10

90

 
  1. DM: diabetes mellitus; ND: not determined; HbA1c: glycated haemoglobin.
  2. Statistical analyses were undertaken using the unpaired t-test, ns: non-significant, ametformin vs. glibenclamide, bmetformin vs. metformin + glibenclamide, cglibenclamide vs. metformin + glibenclamide.
Back to article page